SynAct Pharma AB (8F8.F)

0.5885 +0.0025 (+0.43%) As of 03:29PM CEST. Market open.

SynAct Pharma AB

Medicon Village
Scheelevägen 2
Lund 223 81
Sweden
46 1 03 00 10 23
https://synactpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 5

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jeppe Ovli Ovlesen EE, MBA	CEO & Director	3.66M	N/A	1962
Mr. Bjorn Westberg	Chief Financial Officer	N/A	N/A	1962
Dr. Thomas Boesen Ph.D.	Chief Operating Officer	N/A	N/A	N/A
Mr. James Knight M.B.A.	Chief Business Officer	N/A	N/A	N/A
Ms. Kristen Harting M.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.

Corporate governance

SynAct Pharma AB’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.